Bioventus to be sole US distributor of Supartz Fx through May 2028 — 3 things to know

Written by Shayna Korol | February 12, 2018 | Print  |

Bioventus extended its agreement with Seikagaku Corp. to continue distributing Supartz Fx. Under the terms of this agreement, Bioventus will be Supartz Fx's exclusive distributor in the U.S. through May 2028.

Here are three things to know:

1. Supartz Fx is a five-injection, hyaluronic acid product used for joint lubrication in the treatment of knee osteoarthritis-associated pain.

2. It is indicated for treatment of pain in osteoarthritis of the knee in patients who have failed to adequately respond to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen.

3. Bioventus is an orthobiologics company with product offerings for bone healing, bone graft and knee osteoarthritis. Its Exogen Ultrasound Bone Healing System has been used to treat more than 1 million patients worldwide and has been approved by numerous regulatory agencies, including the FDA, Health Canada, BSI, TGA, Medsafe, UAE Ministry of Health and SFDA.

More articles on biologics:

Osiris names interim CEO welcomes new board member: 3 insights

U.S. Stem Cell reveals the factors driving company growth: 4 insights

Royal Biologics reveals Amnio-Maxx: 4 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months